Clinical Trials

288 enrolled

Papillomavirus Infections

NCT04472377 2024-10-03

HPV Typing Between Self- and Physician-sampled

1,210 enrolled 7 charts

Vaginal Discharge, Papillomavirus Infections

NCT06439433 2024-06-03

ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection

119 enrolled

Papillomavirus Infections

NCT06399341 2024-05-03

PAPILOBSGR

524 enrolled

Papillomavirus Infections

NCT05679141 2024-04-26

Clinical Correlation Between Self-collected and Physician-collected HPV Screening Kits

344 enrolled

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT02634190 2024-02-28

Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HC2® Test Using LBC ThinPrep® Specimens

10,000 enrolled

Papillomavirus Infections

NCT06199128 2024-01-10

Fix

533 enrolled

Papillomavirus Infections

NCT05372016 2023-11-24

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

1,200 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT06111911 2023-11-01

Detection of High-Risk HPV in Urine and Cervical Swab Specimen Using HPV Diagnostic Kit (Bio Farma)

900 enrolled

Papillomavirus Infections

NCT00380367 2023-05-31

Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)

110 enrolled 7 charts

Papillomavirus Infections

NCT03900572 2023-04-13

A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine

90 enrolled

Uterine Cervical Neoplasms, Condylomata Acuminata, Papillomavirus Infections

NCT04965350 2023-04-13

Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females

1,100 enrolled

Papillomavirus Infections

NCT05694728 2023-01-23

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

GastrointestinalGynecologic

780 enrolled

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vulvar Neoplasms, Papillomavirus Infections

NCT05680454 2023-01-17

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

GastrointestinalGynecologic

160 enrolled

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT00943722 2022-10-03

A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)

3,074 enrolled 24 charts

Uterine Cervical Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT01077856 2022-09-13

VIP

54,516 enrolled 29 charts

Congenital Abnormalities, Papillomavirus Infections

NCT01567813 2022-07-22

Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)

114,035 enrolled

DNA Virus Infections, Skin Diseases, Skin Diseases, Infectious, Tumor Virus Infections, Virus Diseases, Warts, Skin Diseases, Viral, Papillomavirus Infections

NCT05426148 2022-06-29

Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female

Phase 4 Completed

540 enrolled

Persistent Infection, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Papillomavirus Infections

NCT04436133 2022-05-06

Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)

480 enrolled

Papillomavirus Infections

NCT05156541 2021-12-14

ING-HPV-1

30 enrolled

Condylomata Acuminata, Papillomavirus Infections

NCT04083196 2021-11-24

A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years

90 enrolled

Papillomavirus Infections

NCT04199260 2021-08-09

PAPILOBS

263 enrolled

Papillomavirus Infections

NCT04002154 2021-02-16

PALOMA

134 enrolled

Papillomavirus Infections

NCT02482428 2021-01-05

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

88 enrolled 10 charts

Condylomata Acuminata, Sexually Transmitted Diseases, Virus Diseases, Papillomavirus Infections

NCT00481767 2020-11-17

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.

676 enrolled 15 charts

Infections, Papillomavirus Infections

NCT00947115 2020-10-30

Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects

525 enrolled 24 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01031069 2020-07-21

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Phase 4 Completed

873 enrolled 34 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT03929172 2020-07-01

A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects

20 enrolled

Papillomavirus Infections

NCT01381575 2020-06-09

Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls

1,447 enrolled 26 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01627561 2020-04-10

Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

148 enrolled 28 charts

Papillomavirus Infections

NCT03546842 2020-02-25

V503-017

201 enrolled 11 charts

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections, Adenocarcinoma in Situ

NCT00877877 2020-01-18

Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.

632 enrolled 28 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00586339 2020-01-03

Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females

150 enrolled 26 charts

Acquired Immunodeficiency Syndrome, Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00637195 2020-01-03

Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

152 enrolled 21 charts

Uterine Cervical Neoplasms, Hepatitis B, Papillomavirus Infections

NCT00250276 2020-01-02

Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.

798 enrolled 19 charts

Papillomavirus Infections

NCT00294047 2020-01-02

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

5,752 enrolled 42 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00359619 2020-01-02

Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine

383 enrolled 28 charts

Papillomavirus Infections

NCT00423046 2020-01-02

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

1,106 enrolled 27 charts

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

NCT00231413 2019-12-12

Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.

383 enrolled 30 charts

Papillomavirus Infections

NCT03158220 2019-11-21

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

1,212 enrolled 15 charts

34,412 enrolled 21 charts

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT00534638 2019-11-15

Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

Phase 4 Completed

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01462357 2019-11-15

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females